About windtree therapeutics - WINT
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
WINT At a Glance
Windtree Therapeutics, Inc.
2600 Kelly Road
Warrington, Pennsylvania 18976-3622
| Phone | 1-215-488-9300 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -1,787,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
WINT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.448 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.166 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.44 |
WINT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -127,642.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
WINT Liquidity
| Current Ratio | 0.45 |
| Quick Ratio | 0.45 |
| Cash Ratio | 0.311 |
WINT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -5.929 |
| Return on Equity | -21.572 |
| Return on Total Capital | -11.914 |
| Return on Invested Capital | -10.706 |
WINT Capital Structure
| Total Debt to Total Equity | 13.827 |
| Total Debt to Total Capital | 12.147 |
| Total Debt to Total Assets | 6.536 |
| Long-Term Debt to Equity | 6.533 |
| Long-Term Debt to Total Capital | 4.354 |